When squint and proptosis signal more: A case of probable paediatric myelin oligodendrocyte glycoprotein antibody-associated disease presenting as optic neuritis.
Main Article Content
Abstract
Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disorder of the central nervous system affecting individuals of all age groups.1,2 Although optic neuritis, acute disseminated encephalomyelitis, and transverse myelitis are typical presentations, paediatric patients demonstrate a distinct clinical phenotype with age-related variation in disease expression.2 Orbital manifestations are uncommon and may lead to diagnostic uncertainty.
Case Presentation: A previously healthy 4-year-old boy presented with acute-onset outward deviation and apparent proptosis of the right eye following a recent episode of pneumonia. Visual acuity was 20/600 in the right eye and 20/40 in the left eye, with a right relative afferent pupillary defect and marked right optic disc swelling with perivascular sheathing. Initial evaluation focused on excluding orbital cellulitis, inflammatory orbital disease, orbital tumour, and orbital apex syndrome. Computed tomography of the orbit and brain was performed to exclude an orbital mass or infectious orbital pathology and demonstrated enlargement of the right optic nerve. Subsequent magnetic resonance imaging revealed optic nerve enhancement consistent with optic neuritis, along with large, poorly defined T2/FLAIR hyperintense lesions involving the bilateral frontal and parietal white matter and the hemicerebellum, suggestive of an inflammatory demyelinating process. Aquaporin-4 antibody was negative, while serum MOG-IgG was reported as borderline positive with a reference cut-off of 1:10 using indirect immunofluorescence antibody testing. However, the quantitative titre and specific criteria for borderline interpretation were unavailable. The patient was treated with intravenous methylprednisolone followed by intravenous immunoglobulin because of an inadequate initial response. Significant clinical improvement was observed at the three-week follow-up, with visual acuity improving to 20/40 in the right eye and resolution of ocular deviation, relative afferent pupillary defect, and optic disc swelling. The patient completed immunotherapy and remained free from ocular relapse or neurological deterioration during two years of follow-up.
Conclusion: This case highlights that optic neuritis associated with MOGAD may present with atypical orbital features, including proptosis and ocular deviation, mimicking primary orbital disease. Early recognition of inflammatory demyelinating optic neuropathy and appropriate neuroimaging are essential for timely diagnosis and treatment. Although definitive serological confirmation was limited by borderline MOG-IgG positivity, the clinical-radiological features and favourable response to immunotherapy supported a diagnosis of probable MOGAD.
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Voase S, Robertson NP. Diagnostic criteria for MOGAD. J Neurol. 2024;271(6):3690-3692.
Banwell B, Bennett JL, Marignier R, Palace J, Chitnis T, Fujihara K, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282.
De Mol CL, Wong YYM, van Pelt ED, Wokke BHA, Siepman TAM, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020;26(7):806-814.
Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, Neuteboom RF, Hemingway C, et al. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody associated disorders. Eur J Paediatr Neurol. 2020;29:2-13.
Nurul-Ain M, Khairul Kamal ZN, Wan Hitam WH, Abd Munaaim M, Mohd Zaki F. Myelin oligodendrocyte glycoprotein optic neuritis: a case series. Cureus. 2021;13:e14452.
Sulaiman FN, Kamardin NF, Sultan Abdul Kader MI, Ch’ng H, Wan Abdul Halim WH. Myelin oligodendrocyte glycoprotein optic neuritis presenting with orbital apex syndrome. Cureus. 2023;15:e38975.
Shah D, Vaishnav G, Singh R, Punamia R, Damani T. Myelin oligodendrocyte glycoprotein antibody positive bilateral optic perineuritis in a young male treated with steroids and fingolimod. IP Int J Ocul Oncol Oculoplasty. 2020;6:263-265.
Armangué T, Olivé-Cirera G, Martínez-Hernández E, Sepúlveda M, Ruiz-García R, Muñoz-Batista M, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020;19(3):234-246.
Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19(10):1261-1267.
Bruijstens AL, Wendel EM, Lechner C, Bartels F, Finke C, Breu M, et al. E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:41-53.
Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol. 2021;89(1):30-41.